Foreground Capital

Millie is an innovative maternity clinic designed to enhance the healthcare experience for expectant and new mothers. Founded by individuals with personal and professional experience in maternity care, the clinic offers a comprehensive range of services to support women throughout their maternal journey. Millie's platform includes remote health monitoring, home postpartum visits, and access to a dedicated application for parenthood support. Additionally, the clinic provides one-on-one doula coaching, ensuring that patients receive extensive care, expert guidance, and continuous support during and after pregnancy. Millie's focus on improving clinical outcomes and streamlining the healthcare experience distinguishes it in the maternity care sector.

Gesynta Pharma AB is a clinical-stage pharmaceutical company based in Stockholm, Sweden, founded in 2017. The company focuses on developing compounds that inhibit the pro-inflammatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions, particularly in cardiovascular diseases and cancer. Its most advanced drug candidate, vipoglanstat (GS-248), is being developed as a non-hormonal treatment for endometriosis, a painful condition affecting around 10 percent of women of reproductive age. Clinical studies have indicated that vipoglanstat significantly reduces endometriotic lesions and provides pain relief, with preparations underway for a phase II clinical trial. Additionally, Gesynta Pharma is advancing another candidate, GS-073, which is set to enter phase I clinical trials for a different inflammatory condition. The company's research is rooted in work from the Karolinska Institutet, and it aims to deliver safe and effective treatments for serious diseases.